Oncology

This is the latest episode of the free DDW podcast, “Mini-library approach delivers an arsenal in drug development pipeline”. It covers a narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. In the article, Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer […]

This is the latest episode of the free DDW podcast, “Mini-library approach delivers an arsenal in drug development pipeline”. It covers a narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. In the article, Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer […]

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s oral inhibitor abemaciclib for the treatment of patients with a specific type of breast cancer.   Abemaciclib will now be able to be used in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human […]

Cancer Research UK has formed a strategic alliance with a research institute in the Netherlands as part of a joint effort to boost understanding into cancer and to translate research in patient benefits.   Cancer Research UK will work with the Stichting Oncode Institute in the Netherlands on a five-year partnership to foster innovation and collaboration […]

This 26-page DDW eBook, sponsored by The Jackson Laboratory, contains exclusive insight from industry experts on: How machine learning is currently used across different stages of cancer research Accelerating research: the path forward for treating rare cancers Immunotherapy challenges and the tools for research Why combination immunotherapies are one of the most exciting ATMPs being […]

Amphista Therapeutics, a company focused on the development of next generation targeted protein degradation (TPD) therapeutics, has signed a strategic collaboration and license agreement with Bristol Myers Squibb.   The companies will work together to discover and develop small molecule protein degraders. Bristol Myers Squibb will be granted a global exclusive license to the degraders developed and will […]

AstraZeneca’s Biologics License Application (BLA) for tremelimumab has been accepted for Priority Review in the US, the company has announced. Tremelimumab is a human monoclonal antibody which AstraZeneca is investigating as a potential therapy for cancers. It works by targeting the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Now, tremelimumab has been accepted for an […]

Biopharma company Biomunex Pharmaceuticals has appointed a new chief scientific officer (CSO) to the company and member of its scientific advisory board.   The company has appointed Dr Simon Plyte as CSO who joins Biomunex to help strengthen its R&D strategy.   Dr Plyte brings a wealth of knowledge and experience, spanning over two decades in R&D […]

Biomedical startup Cannabotech has partnered with the Californian corporation go NXT LVL in a move which will enable it to manufacture cannabidiol products in California.  Specifically, the agreement will allow Cannabotech’s integrative oncology products to be developed and manufactured at Go NXT LVL’s facilities in accordance with the California Medical Cannabis Regulations. The move has […]

The National Institute for Health and Care Excellence (NICE) has overturned a previous decision where it chose not to recommend the immunotherapy BAVENCIO (avelumab) for the treatment of bladder cancer.  The decision comes after avelumab’s developers, Merck KGaA and Pfizer, appealed the prior Final Appraisal Document (FAD) by NICE. Avelumab is now recommended as a maintenance […]